Weber M - Search Results

1

Clinical safety and tolerability of losartan.

Weber M. Weber M. Clin Ther. 1997 Jul-Aug;19(4):604-16; discussion 603. doi: 10.1016/s0149-2918(97)80086-0. Clin Ther. 1997. PMID: 9377606

2

Clinical efficacy of eprosartan.

Weber M. Weber M. Pharmacotherapy. 1999 Apr;19(4 Pt 2):95S-101S. doi: 10.1592/phco.19.7.95s.30950. Pharmacotherapy. 1999. PMID: 10213528 Review.

3

Guidelines for assessing outcomes of antihypertensive treatment.

Weber M. Weber M. Am J Cardiol. 1999 Jul 22;84(2A):2K-4K. doi: 10.1016/s0002-9149(99)00402-6. Am J Cardiol. 1999. PMID: 10437736 Review.

4

Emerging treatments for hypertension: potential role for vasopeptidase inhibition.

Weber M. Weber M. Am J Hypertens. 1999 Nov;12(11 Pt 2):139S-147S. doi: 10.1016/s0895-7061(99)00205-8. Am J Hypertens. 1999. PMID: 10596765 Review.

5

The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?

Sica DA, Weber M. Sica DA, et al. Among authors: weber m. J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4):301-5. doi: 10.1111/j.1524-6175.2002.01099.x. J Clin Hypertens (Greenwich). 2002. PMID: 12147937 Free PMC article. Clinical Trial.

6

Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.

Deedwania P, Weber M, Reimitz PE, Bakris G. Deedwania P, et al. Among authors: weber m. J Clin Hypertens (Greenwich). 2017 Dec;19(12):1309-1318. doi: 10.1111/jch.13103. Epub 2017 Oct 25. J Clin Hypertens (Greenwich). 2017. PMID: 29067756 Free PMC article.

7

Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.

Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Brook RD, et al. Among authors: weber m. J Am Heart Assoc. 2018 Jan 4;7(1):e006940. doi: 10.1161/JAHA.117.006940. J Am Heart Assoc. 2018. PMID: 29301757 Free PMC article.

8

Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.

Kario K, Weber M, Ferrannini E. Kario K, et al. Among authors: weber m. J Clin Hypertens (Greenwich). 2018 Mar;20(3):424-428. doi: 10.1111/jch.13229. Epub 2018 Feb 19. J Clin Hypertens (Greenwich). 2018. PMID: 29457344 Free PMC article. No abstract available.

9

Impact of number of prescribed medications on visit-to-visit variability of blood pressure: implications for design of future trials of renal denervation.

Howard JP, Patel H, Shun-Shin MJ, Mourad JJ, Blacher J, Mahfoud F, Zeller T, Weber M, Francis DP. Howard JP, et al. Among authors: weber m. J Hypertens. 2015 Nov;33(11):2359-67. doi: 10.1097/HJH.0000000000000708. J Hypertens. 2015. PMID: 26372316

10

Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.

Böhm M, Schumacher H, Teo KK, Lonn E, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder R, Weber M, Sliwa K, Williams B, Yusuf S. Böhm M, et al. Among authors: weber m. Eur Heart J. 2018 Sep 1;39(33):3105-3114. doi: 10.1093/eurheartj/ehy287. Eur Heart J. 2018. PMID: 29873709 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,984 results

Search Page